Valuation : Cartesian Therapeutics, Inc.

Market Cap 276M 237M 223M 204M 382M 26.05B 383M 2.64B 1.02B 13.37B 1.04B 1.01B 43.06B P/E 2026 *
-3.1x
P/E 2027 * -2.23x
Enterprise Value 135M 116M 109M 99.79M 187M 12.74B 187M 1.29B 501M 6.54B 507M 496M 21.06B EV / Sales 2026 *
356x
EV / Sales 2027 * -55.1x
Free-Float
47.87%
Yield 2026 *
-
Yield 2027 * -
1 day+1.64%
1 week-3.44%
Current month-0.11%
1 month+15.01%
3 months+41.53%
6 months+17.79%
Current year+28.57%
1 week 8.8
Extreme 8.8
9.64
1 month 8.43
Extreme 8.43
10.88
Current year 5.6
Extreme 5.6
11
1 year 5.6
Extreme 5.6
11
3 years 5.6
Extreme 5.6
42.6
5 years 5.6
Extreme 5.6
42.6
10 years 5.6
Extreme 5.6
42.6
Date Insider Type Main position Quantity % Market Cap. Importance
02/04/26 Exercice 758,001 2.8594%
02/04/26 Exercice 22,740 --
02/04/26 Exercice 22,740 --
Change 5-day change 1-year change 3-year change Capi.($)
+1.64%-3.44%-7.30% - 276M
-1.79%-3.82%+38.74%+91.90% 69.02B
-2.06%-0.18%+41.53%+88.17% 66.32B
-0.31%+6.54%-11.39%+457.82% 27.66B
+0.86%+1.65%+0.25%-14.78% 25.84B
-3.00%-2.61%+34.45%+11.39% 26.54B
-1.46%-0.09%+24.64%-18.36% 20.4B
-2.96%-16.03%+213.13%+375.00% 17.63B
-1.49%-6.69%-4.69%+539.74% 15.15B
-0.20%+8.37%+57.87%+159.50% 14.65B
Average -1.08%-1.45%+38.72%+187.82% 28.35B
Weighted average by Cap. -1.53%-0.46%+39.04%+146.62%

Financials

2026 *2027 *
Net sales 379K 326K 307K 280K 525K 35.81M 526K 3.63M 1.41M 18.37M 1.42M 1.39M 59.18M 250K 215K 202K 185K 346K 23.6M 347K 2.39M 928K 12.11M 939K 918K 39.01M
Net income -87.44M -75.24M -70.79M -64.67M -121M -8.26B -121M -837M -325M -4.24B -328M -321M -13.65B -143M -123M -116M -106M -198M -13.49B -198M -1.37B -531M -6.92B -537M -525M -22.3B
Net Debt -141M -121M -114M -104M -195M -13.31B -196M -1.35B -523M -6.83B -529M -518M -22B -290M -249M -235M -214M -401M -27.35B -402M -2.77B -1.08B -14.03B -1.09B -1.06B -45.21B
Logo Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc. is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.
Employees
75
Date Price Change Volume
04/09/26 $9.270 +1.64% 68,370
03/09/26 $9.120 +0.44% 134,923
02/09/26 $9.080 -2.37% 128,989
01/09/26 $9.300 +0.22% 112,137
31/08/26 $9.280 -3.33% 90,807
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
9.270USD
Average target price
34.57USD
Spread / Average Target
+272.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RNAC Stock